Partially Saturated Bicyclic Heteroaromatics as an sp3‐Enriched Fragment Collection

Abstract Fragment‐based lead generation has proven to be an effective means of identifying high‐quality lead compounds for drug discovery programs. However, the fragment screening sets often used are principally comprised of sp2‐rich aromatic compounds, which limits the structural (and hence biological) diversity of the library. Herein, we describe strategies for the synthesis of a series of partially saturated bicyclic heteroaromatic scaffolds with enhanced sp3 character. Subsequent derivatization led to a fragment collection featuring regio‐ and stereo‐controlled introduction of substituents on the saturated ring system, often with formation of new stereocenters.

[1]  Nathan Brown,et al.  Fragment-based hit identification: thinking in 3D. , 2013, Drug discovery today.

[2]  Beat Ernst,et al.  Drug discovery today. , 2003, Current topics in medicinal chemistry.

[3]  John M. Brown,et al.  The Scope of Catalytic Asymmetric Hydroboration/Oxidation with Rhodium Complexes of 1,1′-(2-Diarylphosphino-1-naphthyl)isoquinolines , 1999 .

[4]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[5]  P. Hirth,et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.

[6]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[7]  N. Borkakoti,et al.  Design and synthesis of potent hydroxyethylamine (HEA) BACE-1 inhibitors carrying prime side 4,5,6,7-tetrahydrobenzazole and 4,5,6,7-tetrahydropyridinoazole templates. , 2012, Bioorganic & medicinal chemistry letters.

[8]  Fangming Jin,et al.  Synthesis of allylated quinolines/isoquinolines via palladium-catalyzed cyclization-allylation of azides and allyl methyl carbonate. , 2015, Organic & biomolecular chemistry.

[9]  Louis-Charles Campeau,et al.  Cobalt-Catalyzed Enantioselective Hydrogenation of Minimally Functionalized Alkenes: Isotopic Labeling Provides Insight into the Origin of Stereoselectivity and Alkene Insertion Preferences. , 2016, Journal of the American Chemical Society.

[10]  A. V. D. Hoogenband,et al.  A straightforward synthesis of 1,3-dichloro-5,8-dihydroisoquinoline by consecutive Stille cross-coupling and metathesis reactions , 2009 .

[11]  David R. Spring,et al.  The Use of Chlorobenzene as a Probe Molecule in Molecular Dynamics Simulations , 2014, J. Chem. Inf. Model..

[12]  Warren R. J. D. Galloway,et al.  Drug discovery: A question of library design , 2011, Nature.

[13]  D. Spring,et al.  Diversity-oriented synthesis of drug-like macrocyclic scaffolds using an orthogonal organo- and metal catalysis strategy. , 2014, Angewandte Chemie.

[14]  J. Herndon.  The chemistry of the carbon-transition metal double and triple bond: Annual survey covering the year 2013☆ , 2015 .

[15]  T. Moss.  A ring-closing metathesis approach to heterocycle-fused azepines , 2013 .

[16]  C. W. Murray,et al.  Organische Chemie für die fragmentbasierte Wirkstoffentwicklung (FBDD) , 2016 .

[17]  Isabelle Krimm,et al.  Ligand specificity, privileged substructures and protein druggability from fragment-based screening. , 2011, Current opinion in chemical biology.

[18]  D. Procter,et al.  Nucleophilic ortho-Allylation of Pyrroles and Pyrazoles: An Accelerated Pummerer/Thio-Claisen Rearrangement Sequence , 2013, Organic letters.

[19]  Roderick E Hubbard,et al.  Experiences in fragment-based lead discovery. , 2011, Methods in enzymology.

[20]  Stephen D Pickett,et al.  Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia. , 2016, Journal of medicinal chemistry.

[21]  T. Ritchie,et al.  The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design? , 2009, Drug discovery today.

[22]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[23]  T. Sarkar,et al.  A diversity-oriented synthesis of bicyclic cis-dihydroarenediols, cis-4-hydroxyscytalones, and bicyclic conduritol analogues. , 2010, Organic letters.

[24]  T. Maurer,et al.  Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. , 2010, Bioorganic & medicinal chemistry letters.

[25]  O. R. Gautun,et al.  Asymmetric catalytic aziridination of dihydronaphthalenes for the preparation of substituted 2-aminotetralins , 2010 .

[26]  Monya Baker,et al.  Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.

[27]  Adam Nelson,et al.  Synthesis of Natural-Product-Like Molecules with Over Eighty Distinct Scaffolds** , 2008, Angewandte Chemie.

[28]  M. Maestro,et al.  An Approach to 2,4-Substituted Pyrazolo[1,5-a]pyridines and Pyrazolo[1,5-a]azepines by Ring-Closing Metathesis , 2013 .

[29]  Stefan Wetzel,et al.  Natural-product-derived fragments for fragment-based ligand discovery , 2012, Nature Chemistry.

[30]  Y. Murthy,et al.  Reagent-based DOS: developing a diastereoselective methodology to access spirocyclic- and fused heterocyclic ring systems. , 2012, Chemistry, an Asian journal.

[31]  K. Mohanan,et al.  Domino reaction involving the Bestmann-Ohira reagent and α,β-unsaturated aldehydes: efficient synthesis of functionalized pyrazoles. , 2015, Organic & biomolecular chemistry.

[32]  Nick Palmer,et al.  Design and synthesis of dihydroisoquinolones for fragment-based drug discovery (FBDD). , 2016, Organic & biomolecular chemistry.

[33]  T. Bach,et al.  Enantio- and regioselective epoxidation of olefinic double bonds in quinolones, pyridones, and amides catalyzed by a ruthenium porphyrin catalyst with a hydrogen bonding site. , 2012, Journal of the American Chemical Society.

[34]  J. Macor,et al.  Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine. , 2012, ACS medicinal chemistry letters.

[35]  P. McEwan,et al.  Tetrahydroindazoles as Interleukin-2 Inducible T-Cell Kinase Inhibitors. Part II. Second-Generation Analogues with Enhanced Potency, Selectivity, and Pharmacodynamic Modulation in Vivo. , 2015, Journal of medicinal chemistry.

[36]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[37]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[38]  Edward R Zartler,et al.  Fragonomics: the -omics with real impact. , 2014, ACS medicinal chemistry letters.

[39]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[40]  Christopher W Murray,et al.  Opportunity Knocks: Organic Chemistry for Fragment-Based Drug Discovery (FBDD). , 2016, Angewandte Chemie.

[41]  P. Clemons,et al.  Route to three-dimensional fragments using diversity-oriented synthesis , 2011, Proceedings of the National Academy of Sciences.